ClinicalTrials.gg
Not yet recruitingNCT07447115Updated Mar 3, 2026

Exercise With and Without Cognitive Training

An interventional study of Effect of Exercise with and Without Cognitive Training on Gait in Multiple Sclerosis, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Multiple Sclerosis by VA Office of Research and Development — 2 open to participants now, 2 under way, none of them phase 3. Multiple Sclerosis · VA Office of Research and Development.

Planned enrollment
13th of 17
30 · median 52
Started
2027
the only one that year
No phase
10 of 17
2 open now
Registered
17th of 17
by date

Among the 17 studies in Multiple Sclerosis by VA Office of Research and Development, this one is the 13th largest by planned enrollment, is the only one that started in 2027, is one of 10 with no phase, and was the 17th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 17 studies in Multiple Sclerosis by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Multiple Sclerosis by VA Office of Research and Development, or all of them as a file.
02

Study summary

This proposal aims to conduct a 10-week randomized controlled trial comparing walking and resistance training with and without computerized cognitive training in older Veterans with Multiple Sclerosis, followed by 12 months of fall tracking with sensors and fall calendars. The primary objectives of this proposed CDA2 are to provide critical preliminary data on 1) the feasibility of conducting a 10-week RCT, 2) preliminary treatment effects on gait, cognition, and falls, and 3) neuroinflammatory biomarkers. Dr. Katherine Hsieh will receive hands-on training in the design and conduct of clinical trials (Dr. Hackney), mechanisms underlying physical activity, cognitive rehabilitation, and falls (Drs. Twamley, Hackney, \& Kesar), fall detection technology (Prof. Sanford), and clinical problems faced by MS participants (Dr. Backus) to achieve her long-term career goal of becoming an independent falls prevention investigator.

Read the detailed description

Significance to VA: A key aim of this proposal is to equip Dr. Katherine Hsieh with the expertise to become an independent VA investigator leading fall prevention trials for older Veterans with Multiple Sclerosis (MS). MS is a chronic, neurodegenerative disease affecting 55,00-70,000 Veterans. Over 28,000 MS cases are reported annually to the VA, and within the Paralyzed Veterans of America, 1 in 4 members have MS. Gait and cognitive impairments are the two of the most common MS symptoms and two of the most important predictors of falls, which lead to fractures, disability, and even death. Adults 55 years and older are the largest group of people living with MS, and the combination of MS symptoms and aging puts older MS Veterans at a high risk of falls. Preventing falls in older Veterans with MS is needed to improve their independence and quality of life. Innovation and Impact: This proposal seeks to utilize an innovative method of combining walking and resistance training with computerized cognitive training on fall risk outcomes. Falls are associated with slower gait speed and declines in processing speed, attention, executive function, and verbal memory. In people with MS, walking and resistance training improves gait function, and computerized cognitive training improves executive functions, processing speed, and attention. Whether combining computerized cognitive training with walking and resistance training provides additional benefits to gait, cognition, and falls remains unclear. Specific Aims: The objectives of this CDA2 proposal are to: 1) determine the feasibility of conducting a 10-week RCT comparing walking and resistance training with and without computerized cognitive training; 2) obtain estimates of intervention effects on gait, cognitive function, and prospective falls; 3) explore neuroinflammatory mechanisms underlying treatment effects. In addition, the PI has established a team of mentors (Drs. Hackney, Twamley, Sanford, Backus, and Kesar) to achieve five career development goals: 1) advance knowledge in the design and conduct of clinical trials; 2) examine mechanisms underlying physical activity, cognitive rehabilitation, and falls in older MS Veterans; 3) develop expertise in the use and implementation of fall detection technology; 4) acquire basic knowledge of clinical problems faced by people with MS; and 5) enhance professional skills including grant writing, scientific communication, and mentorship. Methodology: This trial will enroll 30 older Veterans with MS aged 55 or older randomized to 10 weeks, 3x/week of walking and resistance exercises with computerized cognitive training (n=15) or computer games (n=15). Participants will complete a battery of physical and cognitive tasks at baseline and 10-week follow-up. Following the intervention, the investigators will track falls for 12 months with an Apple watch and fall calendars. Aim 1, feasibility, will be measured with randomization, adherence, retention, and satisfaction to the 10-week trial. Aim 2 will compare gait and mobility, cognition, and future falls between intervention groups. Aim 3 will explore neuroprotective responses using brain-derived neurotrophic factor, interleukin-6, and tumor necrosis alpha to examine group differences and explore subgroup analyses.

Path to Translation/Implementation: Results of this study will provide critical preliminary data on gait, cognition, and falls to power and inform a full-scale RCT as the investigator's next Parent Merit. The investigators will also possess pilot data on biomarkers to identify responders and non-responders and target specific subgroups. Ultimately, this study aims to implement exercise and cognitive training to maximize functional independence for older Veterans with MS. In addition, leading this RCT and longitudinal study, along with taking didactic coursework and training, will help the investigator accomplish her long-term career goal to become an independent falls prevention investigator. By the conclusion of this CDA2, the investigator will possess the knowledge, skills, abilities, and preliminary data necessary to successfully compete for a Parent Merit award and launch her career as a VA falls prevention scientist.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Aging
  • Multiple Sclerosis
  • Mobility
  • Walking
  • Cognition
  • Rehabilitation
  • Falls
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • US Veteran
  • Diagnosis of Multiple Sclerosis
  • Relapse free in the last 30 days
  • Capable of standing unaided for at least 1 minute
  • Expanded Disability Status Scale \<6.5
  • Ability to speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Any neurological disorder other than MS
  • Modified Telephone Interview for Cognitive Status \<20
  • Current participation in an exercise or cognitive rehabilitation study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Computerized Cognitive Training

    This group will complete 75 minutes of walking and resistance exercises followed by computerized cognitive training. Exercises will include treadmill walking and resistance training using bodyweight, dumbbells, and/or bands, following guidelines from the National MS Society. Progression and intensity will be individualized and gradual over time. Sessions are 3x per week for 10 weeks. After a cool-down, participants will use RehaCom for 30 minutes. Cognitive modules will progress in difficulty and tailored. Modules will target attention, executive function, logical reasoning, and memory.

    Behavioral: Effect of Exercise with and Without Cognitive Training on Gait

  • Active comparator
    Active Control

    This group will complete the same exercises as the experimental group. After their cool-down, they will use a computer for 30 minutes to play puzzle games. These games were not developed to provide cognitive rehabilitation. Games will vary each session.

    Behavioral: Effect of Exercise with and Without Cognitive Training on Gait

Interventions

  • BehavioralEffect of Exercise with and Without Cognitive Training on Gait

    This behavioral trial aims to determine the effect of exercise with and without computerized cognitive training on gait in older Veterans with Multiple Sclerosis.

06

What researchers measure

Primary outcomes

  1. Gait speed

    Participants will walk 10m at their usual and fast speeds to measure gait speed in meters/second.

    Time frame: Baseline & 10-week Follow-up

  2. Exit questionnaire

    Satisfaction will be examined with an exit questionnaire that uses a Likert questionnaire (5 point scale) to assay enjoyment of the intervention, willingness to continue with the intervention should participants have the opportunity and whether the participants noted improvement in aspects of well being, e.g., mood, quality of life, mental activity, physical activity, and whether the participants noted improvement in motor function, eg gait, balance, strength, etc.

    Time frame: 10-week Follow-up

Secondary outcomes

  1. Static Postural Control

    Participants will stand for 30 seconds in challenging balance conditions. Time (in seconds) before needing to take a recovery step will be measured.

    Time frame: Baseline & 10-week Follow-up

  2. Symbol Digit Modality Test

    This is a test of processing speed. Participants are asked to match symbols with corresponding numbers. The score is the number of correctly matched symbols within two minutes.

    Time frame: Baseline & 10-week Follow-up

  3. California Verbal Learning Test

    This is a test of memory. Participants are read a list of words and asked to memorize them over the course of 5 trials. The scale ranges from 1-15 with higher scores being better.

    Time frame: Baseline & 10-week Follow-up

  4. Falls efficacy scale (FES)

    This is a 16-item questionnaire to measure fear of falling when doing different activities. Scale ranges from 16-64.

    Time frame: Baseline & 10-week Follow-up

  5. Number of falls per month

    Number of falls will be tracked via fall calendars or sensors for 12 months following the intervention.

    Time frame: 1 year follow up after intervention, e.g., at 15 months.

  6. Brain-derived neurotrophic factor

    BDNF will be measured in picograms/mL to determine neurotrophic effects from the intervention

    Time frame: Baseline & 10-week Follow-up

  7. Tumor necrosis alpha

    TNF-alpha will be measured in picograms/mL to determine inflammatory effects from the intervention

    Time frame: Baseline & 10-week Follow-up

  8. Interleukin-6

    IL-6 will be measured to determine inflammatory effects from the intervention

    Time frame: Baseline & 10-week Follow-up

  9. Time to complete the Timed Up and Go

    Begin sitting in a chair, walk 3 meters, turn around a cone, and walk back and sit in the chair. The time to complete the TUG is measured in seconds.

    Time frame: Baseline & 10-week Follow-up

  10. Brief Visuospatial Memory Test

    Participants are presented an image for 10 seconds and asked to reproduce the image.

    Time frame: Baseline & 10-week Follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 3, 2026
StartEst.
Jan 4, 2027
Primary completionEst.
Jan 4, 2028
CompletionEst.
May 1, 2028
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447115
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Jan 4, 2027 (estimated)
Primary completion
Jan 4, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Mar 3, 2026

Study contacts

Katherine Hsieh, PhD
Contact
khsieh5@gsu.edu
(404) 321-6111
Madeleine E Hackney, PhD
Contact
mehackn@emory.edu
(404) 321-6111 ext. 5006
Katherine Hsieh, PhD
principal investigator · Atlanta VA Medical and Rehab Center, Decatur, GA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion